Table 3. . Comparison between registration trials, large randomized controlled trials using cisplatin/gemcitabine as control arm and our retrospective study.

Trial data	Cardenal et al. (all NSCLC) [8]	Sandler et al. (all NSCLC) [9]	Schiller et al. (all NSCLC) [17]	Scagliotti et al. (nonsquamous subgroup) [10]	Reck et al. (nonsquamous) [12,13]	Kohutek et al. (nonsquamous)
Number of patients	69	260	288	634	347	56
Treatment used	GEM 1250 mg/m2 D1, D8 + cisplatin 100 mg/m2 D1 3-week cycle (up to 6 cycles)	GEM 1000 mg/m2 D1, D8, D15 + cisplatin 100 mg/m2 D1 4-week cycle (up to 5 cycles)		GEM 1250 mg/m2 D1, D8 + cisplatin 75 mg/m2 D1 3-week cycle (up to 6 cycles)	GEM 1250 mg/m2 D1, D8 + cisplatin 80 mg/m2 D1 3-week cycle (up to 6 cycles)	GEM 1250 mg/m2 D1 and D8 ± cisplatin 75 mg/m2 or carboplatin AUC5 D1 3-week cycle (1–6 cycles)
Median PFS (months)	6.9 (TTP)	5.6 (TTP)	4.2 (TTP)	4.7	6.1	6.48
Median OS (months)	8.7	9.1	8.1	10.4	13.1	10.8

D: Day; GEM: Gemcitabine; OS: Overall survival; PFS: Progression-free survival; PS: Performance status; TTP: Time to progression.